We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 20

Blockbuster drug goes bust? The Federal Court finds three AstraZeneca patents relating to Crestor (rosuvastatin) invalid

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 7 2013

In an important decision handed down on Tuesday, Justice Jagot of the Federal Court held that three patents relating to the blockbuster drug Crestor

ACCC joins NRM to Advanced Medical Institute proceedings, alleging unfair contract terms

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • November 3 2011

On 7 September 2011, the ACCC announced that the Federal Court had granted orders to add NRM Corporation Pty Ltd and NRM Trading Pty Ltd as respondents in the ACCC’s existing case against Advanced Medical Institute for alleged unconscionable conduct

European Court of Justice says no to patents requiring the destruction of a human embryo - an Australian perspective

  • King & Wood Mallesons
  • -
  • Australia, European Union
  • -
  • October 20 2011

Article 6(2)(c) of the European Biotech Directive excludes inventions which use human embryos for industrial or commercial purposes from patentability

Experimental evidence comply with the rules or risk inadmissibility

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • March 22 2013

By refusing to allow Generic Health to adduce experimental evidence in a patent case currently being heard in the Federal Court, Justice Jagot has

Pharmaceuticals - copyright in PIs and indirect patent infringement

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • August 4 2011

In the recent decision in Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3), Justice Jagot of the Federal Court found liability for indirect patent infringement in the context of supply of a pharmaceutical product

European Commission ups the cost of paying for delay

  • King & Wood Mallesons
  • -
  • Australia, European Union, USA
  • -
  • August 13 2012

On 25 July 2012, the EC alleged that Danish pharmaceutical company Lundbeck violated EU antitrust rules by colluding to prevent other pharma companies from marketing generic versions of its best-seller antidepressant, citalopram

Breaking news High Court hands down important decision in relation to infringement of pharmaceutical patents

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • December 4 2013

A few hours ago, the High Court handed down its long awaited decision in Apotex v Sanofi. While the High Court confirmed that methods of medical

Just genes? Lessons from the Myriad litigation

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • August 19 2013

Last month the United States Supreme Court ruled that certain naturally occurring DNA sequences (the BRCA1 and BRCA2 genes, mutations in which are

Competition regulators continue their campaign against pharmaceutical companies

  • King & Wood Mallesons
  • -
  • Australia, USA
  • -
  • June 1 2011

Last month, the US Federal Trade Commission (FTC) released its findings on reverse payment settlements between pharmaceutical companies in the 2010 US fiscal year

Australian court decides important gene patenting question isolated genetic material patentable subject matter

  • King & Wood Mallesons
  • -
  • Australia
  • -
  • February 15 2013

Earlier today, the Federal Court rejected a claim brought by Cancer Voices Australia that isolated genetic material (DNA or RNA) that is naturally